RNAZ Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 23:00):

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease...

Stats
Šios dienos apimtis	1.11M
Vidutinė apimtis	509 146
Rinkos kapitalizacija	3.86M
EPS	$0 ( 2024-03-29 )
Kita pelno data	( $0 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.00200 (0.34%)

Insider Trading

Date	Person	Action	Amount	type
2023-09-28	Fitzgerald Thomas A	Buy	49 350	Common Stock
2023-09-28	Dudley Robert Michael	Buy	98 000	Common Stock
2023-06-21	Dudley Robert Michael	Buy	12 000	Common Stock
2023-06-20	Dudley Robert Michael	Buy	6 607	Common Stock
2023-06-09	Dudley Robert Michael	Buy	19 000	Common Stock

INSIDER POWER
100.00
Last 36 transactions
Buy: 2 048 457 \| Sell: 1 170 653

Tūris Koreliacija

Ilgas: 0.35 (neutral)

Trumpas: 0.70 (moderate)

Signal:(37.238) Neutral

TransCode Therapeutics, Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
APOP	0.933
MAGS	0.88
CMLF	0.856
RMRM	0.838

10 Labiausiai neigiamai susiję koreliacijos
MXIM	-0.807
MMAC	-0.805
WLTW	-0.805

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

TransCode Therapeutics, Koreliacija - Valiuta/Žaliavos

0.50
( weak )

0.52
( weak )

0.00
( neutral )

0.57
( weak )

-0.85
( strong negative )

-0.28
( neutral )

TransCode Therapeutics, Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-516 746 (0.00 %)
EPS:	$-103.61

FY	2023
Pajamos:	$0
Bruto pelnas:	$-516 746 (0.00 %)
EPS:	$-103.61

FY	2022
Pajamos:	$0
Bruto pelnas:	$-98 606.00 (0.00 %)
EPS:	$-2 165.71

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-1.133

Financial Reports:

No articles found.

TransCode Therapeutics,

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.